Lexaria Bioscience/$LEXX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Lexaria Bioscience
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
Ticker
$LEXX
Sector
Primary listing
Employees
7
Headquarters
Kelowna, Canada
Website
LEXX Metrics
BasicAdvanced
$15M
-
-$0.66
0.63
-
Price and volume
Market cap
$15M
Beta
0.63
52-week high
$1.90
52-week low
$0.68
Average daily volume
267K
Financial strength
Current ratio
2.322
Quick ratio
1.564
Long term debt to equity
3.032
Total debt to equity
4.2
Profitability
EBITDA (TTM)
-11.546
Gross margin (TTM)
99.61%
Net profit margin (TTM)
-1,686.00%
Operating margin (TTM)
-1,648.02%
Revenue per employee (TTM)
$100,000
Management effectiveness
Return on assets (TTM)
-111.49%
Return on equity (TTM)
-232.15%
Valuation
Price to revenue (TTM)
17.468
Price to book
4.46
Price to tangible book (TTM)
4.97
Price to free cash flow (TTM)
-1.169
Free cash flow yield (TTM)
-85.56%
Free cash flow per share (TTM)
-0.586
Growth
Revenue change (TTM)
52.05%
Earnings per share change (TTM)
41.30%
3-year revenue growth (CAGR)
40.34%
10-year revenue growth (CAGR)
47.28%
3-year earnings per share growth (CAGR)
-18.80%
10-year earnings per share growth (CAGR)
-6.80%
LEXX News
AllArticlesVideos
Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Accesswire·3 days ago
Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
TheNewswire·3 days ago
Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Accesswire·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lexaria Bioscience stock?
Lexaria Bioscience (LEXX) has a market cap of $15M as of December 19, 2025.
What is the P/E ratio for Lexaria Bioscience stock?
The price to earnings (P/E) ratio for Lexaria Bioscience (LEXX) stock is 0 as of December 19, 2025.
Does Lexaria Bioscience stock pay dividends?
No, Lexaria Bioscience (LEXX) stock does not pay dividends to its shareholders as of December 19, 2025.
When is the next Lexaria Bioscience dividend payment date?
Lexaria Bioscience (LEXX) stock does not pay dividends to its shareholders.
What is the beta indicator for Lexaria Bioscience?
Lexaria Bioscience (LEXX) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.